Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience reports promising interim results in a diabetes animal study, where their DehydraTECH technology, combined with diabetes drugs, has shown significant potential in reducing body weight. Specifically, the DehydraTECH-CBD and DehydraTECH-liraglutide formulations have yielded the most notable weight loss in the study to date.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.